HANSA MEDICAL AB ORD news, videos and press releases - Page 4
For more news please use our advanced search feature.
HANSA MEDICAL AB ORD - More news...
HANSA MEDICAL AB ORD - More news...
- Hansa Biopharma Nomination Committee formed
- Hansa Biopharma announces it has confidentially submitted a draft registration statement on Form F-1 to the U.S. SEC relating to a potential U.S. IPO
- Hansa Biopharma interim report Jan-Sept 2021
- Hansa Biopharma presented new data on imlifidase at the European Society for Organ Transplantation (ESOT) Congress
- Hansa Biopharma announces participation in Fall investor conferences and provides updated financial calendar
- Hansa Biopharma achieves Great Place to Work certification for second consecutive year
- Hansa Biopharma announces reimbursement in the Netherlands of Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
- Hansa Biopharma announces long term follow-up data demonstrating 3-year graft survival of 84% after imlifidase treatment and transplantation
- Hansa Biopharma to host conference call to provide interim results for first half 2021 and Business Update
- Hansa Biopharma announces decision by Swedish New Therapies Council to recommend use of Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
- Hansa Biopharma announces study design for a US randomized, controlled trial of imlifidase in highly sensitized kidney transplant patients
- Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
- Hansa Biopharma interim report Jan-Mar 2021
- Hansa Biopharma to host conference call to provide interim results from Q1 2021 and Business Update
- Hansa Biopharma: Notice to Annual General Meeting
- Hansa Biopharma enters preclinical research collaboration with argenx
- Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development
- Hansa Biopharma to host conference call to provide Year-End report 2020 and Business Update
- Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference
- Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference
- Hansa Biopharma Nomination Committee formed
- Hansa Biopharma interim report Jan-Sep 2020
- Hansa Biopharm announces positive high-level data from investigator-initiated phase 2 trial with imlifidase to treat anti-GBM disease
- Hansa Biopharma to host Capital Markets Day on Thursday October 29, 2020 in Copenhagen
- Hansa Biopharma provides updated guidance on its clinical programs
- Hansa Biopharma announces participation in Fall conferences and an updated financial calendar
- The EU Commission grants conditional approval for IdefirixTM (imlifidase) in highly sensitized kidney transplant patients in the European Union
- Hansa Biopharma announces increase in number of shares and votes
- Hansa Biopharma Interim Report Jan-Jun 2020
- Hansa Biopharma Announces Exclusive Agreement With Sarepta Therapeutics to Develop and Promote Imlifidase as Pre-treatment Ahead of Gene Therapy in Select Indications
